Page 232 - 2021_06-Haematologica-web

Letters to the Editor
Correspondence:
CYRILLE HULIN - cyrille.hulin@chu-bordeaux.fr doi:10.3324/haematol.2020.261842
Received: June 9, 2020.
Accepted: February 18, 2021.
Pre-published: March 4, 2021.
References
1. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv52-iv61.
2.Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228-1263.
3. Corso A, Caberlon S, Pagnucco G, et al. Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant. 2000;26(3):283-286.
4.Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311-321.
5. Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016; 197(3):807-813.
6. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
7. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T- cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
8. Adams HC III, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modula- tion as a novel mechanism of action. Cytometry A. 2019;95(3):279-
9. Casneuf T, Adams HC III, van de Donk N, et al. Deep immune pro- filing of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021;35(2):573-584.
10. DARZALEX® (daratumumab) injection, for intravenous use [pack- age insert]. Horsham, PA: Janssen Biotech, Inc. 2020. https://www.janssenlabels.com/package-insert/product-mono- graph/prescribing-information/DARZALEX-pi.pdf
11. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dex- amethasone with or without daratumumab before and after autolo- gous stem-cell transplantation for newly diagnosed multiple myelo- ma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38.
12. Ma X, Wong SW, Zhou P, et al. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018;7:27.
13. Ungerstedt JS, Watz E, Uttervall K, et al. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Med Oncol. 2012;29(3):2191-2199.
14. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006; 134(5):517-525.
15. Shah EE, Young RP, Wong SW, et al. Impact of plerixafor use at dif- ferent peripheral blood CD34(+) thresholds on autologous stem cell collection in patients with multiple myeloma. Biol Blood Marrow Transplant. 2020;26(5):876-883.
Disclosures: CH has received honoraria from Celgene, Janssen,
Amgen, and Takeda; and travel, accommodations, and expenses from
Celgene, Janssen, and Amgen. PM has received honoraria from and
served as a consultant or in an advisory role for Celgene, Janssen,
Amgen, and AbbVie. MR has received research funding from Amgen,
Janssen, Takeda, and Celgene; travel, accommodation, and expenses
from Amgen, Janssen, Celgene, Takeda, and Sanofi; and lecture fees
from Amgen, Janssen, Celgene, and Takeda. KB has received personal
fees from Celgene, Amgen, Takeda, and Janssen. TF has severed as a
consultant or in an advisory role, participated in a speakers’ bureau,
and received travel, accommodations, or expenses from Janssen. LG
has served as a consultant or in an advisory role for Amgen, Celgene,
Takeda, Novartis, and Janssen. A-MS has received honoraria from
Janssen, Celgene, Amgen, Novartis, and Takeda. LP, VV, CB, JV
and TK are employees of Janssen Research & Development.
PS has received research funding and/or honoraria from Amgen,
Celgene, Janssen, Karyopharm, and Bristol Myers Squibb. NWCJD
has served as a consultant or in an advisory role for Janssen, Celgene,
Bristol Myers Squibb, Amgen, Novartis, Bayer, Servier, and Takeda;
and has received research funding from Janssen, Celgene, Bristol 289.
Myers Squibb, Amgen, and Novartis. FO, LB, DC, BK, MT, K-SJ, MW and JL have nothing to disclose.
Contributions: CH, FO, PM, MR, KB, LB, DC, TF, LG, FK, A-MS, BK, MT, K-SJ, MW, PS, and NWCJvdD enrolled patients and collected data; NWCJvdD, JL, LP, VV, CdB, JV, and TK analyzed the data. All authors interpreted the data, contributed to the drafting and critical review of the manuscript, and approved the final version for submission. Janssen Research & Development, LLC, the Intergroupe Francophone du Myélome (IFM), and the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) collaborated to design the study.
Acknowledgments: the Intergroupe Francophone du Myélome (IFM) and Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) sponsored this trial. This analysis was funded by Janssen Global Services, LLC. The authors, IFM, HOVON, and Janssen gratefully acknowledge the valued scientific contribution from Dr. Brigitte Kolb. Dr. Kolb passed away on the 5th of October, 2020, and will be dearly missed by the research teams that she contributed to or led. The authors would also like to thank the patients who participated in this study and their families, study investigators, staff members at each study site, and staff members involved in data collection and analyses. Medical writing and editorial support were provided by Kimberly Carmony, PhD, and Grace Wang, PharmD, of MedErgy, and were funded by Janssen Global Services, LLC.
2260
haematologica | 2021; 106(8)